Maria Yu

951 total citations
33 papers, 728 citations indexed

About

Maria Yu is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Family Practice. According to data from OpenAlex, Maria Yu has authored 33 papers receiving a total of 728 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Molecular Biology and 8 papers in Family Practice. Recurrent topics in Maria Yu's work include Diabetes Treatment and Management (28 papers), Metabolism, Diabetes, and Cancer (16 papers) and Diabetes Management and Research (15 papers). Maria Yu is often cited by papers focused on Diabetes Treatment and Management (28 papers), Metabolism, Diabetes, and Cancer (16 papers) and Diabetes Management and Research (15 papers). Maria Yu collaborates with scholars based in United States, Canada and United Kingdom. Maria Yu's co-authors include Reema Mody, Laura Fernández Landó, Michael Grabner, Kristina S. Boye, Hiren Patel, Ralph Swindle, Anita Y. M. Kwan, Abdul Jabbar, Salem Beshyah and Mohamed Hassanein and has published in prestigious journals such as Diabetes, Diabetes Obesity and Metabolism and Diabetes Research and Clinical Practice.

In The Last Decade

Maria Yu

32 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maria Yu United States	15	623	294	138	116	107	33	728
SE Inzucchi Germany	3	613 1.0×	232 0.8×	187 1.4×	39 0.3×	59 0.6×	6	670
Jeffrey Unger United States	9	741 1.2×	374 1.3×	200 1.4×	95 0.8×	168 1.6×	15	855
K. Jameson United Kingdom	9	463 0.7×	93 0.3×	147 1.1×	54 0.5×	51 0.5×	14	613
Andreas Liebl Germany	10	426 0.7×	121 0.4×	93 0.7×	55 0.5×	37 0.3×	17	509
Melissa Magwire United States	8	547 0.9×	156 0.5×	166 1.2×	57 0.5×	78 0.7×	21	672
Jessie L. Fahrbach United States	12	1.1k 1.7×	462 1.6×	281 2.0×	84 0.7×	183 1.7×	19	1.1k
Nor Azmi Kamaruddin Malaysia	4	652 1.0×	372 1.3×	267 1.9×	70 0.6×	179 1.7×	7	731
Tomoyuki Nishida Japan	14	672 1.1×	324 1.1×	173 1.3×	86 0.7×	187 1.7×	26	723
RM Bergenstal United States	4	1.6k 2.6×	380 1.3×	363 2.6×	117 1.0×	99 0.9×	10	1.7k
Margaret Tiktin United States	6	336 0.5×	86 0.3×	64 0.5×	52 0.4×	27 0.3×	7	480

Countries citing papers authored by Maria Yu

Since Specialization

Citations

This map shows the geographic impact of Maria Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Yu more than expected).

Fields of papers citing papers by Maria Yu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Yu. The network helps show where Maria Yu may publish in the future.

Co-authorship network of co-authors of Maria Yu

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Yu. A scholar is included among the top collaborators of Maria Yu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Yu. Maria Yu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nair, Radhika, et al.. (2022). Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study. Diabetes Therapy. 13(11-12). 1921–1932. 20 indexed citations

Mody, Reema, Janna Manjelievskaia, Elizabeth Marchlewicz, et al.. (2022). Greater Adherence and Persistence with Injectable Dulaglutide Compared with Injectable Semaglutide at 1-Year Follow-up: Data from US Clinical Practice. Clinical Therapeutics. 44(4). 537–554. 13 indexed citations

Yu, Maria, et al.. (2022). Association of Dulaglutide Initiation Timing With Treatment Patterns and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus in the United States. Clinical Therapeutics. 44(6). 873–887. 1 indexed citations

Giorgino, Francesco, et al.. (2022). 746-P: The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients (TROPHIES) : Final 24-Month Primary Endpoint Analysis. Diabetes. 71(Supplement_1). 1 indexed citations

Mody, Reema, Maria Yu, Michael Grabner, et al.. (2020). Dulaglutide Shows Sustained Reduction in Glycosylated Hemoglobin Values: 2-Year US Real-world Study Results. Clinical Therapeutics. 42(11). 2184–2195. 6 indexed citations

Mody, Reema, Maria Yu, Bal Nepal, Маниге Кониг, & Michael Grabner. (2020). 928-P: Dulaglutide Has Higher Adherence and Persistence than Semaglutide and Exenatide QW: 6-Month Follow-Up from U.S. Real-World Data. Diabetes. 69(Supplement_1). 4 indexed citations

Matza, Louis S., Kristina S. Boye, Katie D. Stewart, et al.. (2019). Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Diabetes Obesity and Metabolism. 22(3). 355–364. 32 indexed citations

Giorgino, Francesco, Maria Yu, Axel Haupt, Zvonko Miličević, & Luis‐Emilio García‐Pérez. (2019). Effect of once‐weekly dulaglutide versus insulin glargine in people with type 2 diabetes and different baseline glycaemic patterns: A post hoc analysis of the AWARD‐2 clinical trial. Diabetes Obesity and Metabolism. 21(11). 2570–2575. 8 indexed citations

Mody, Reema, Qing Huang, Maria Yu, et al.. (2019). 1259-P: Adherence and Persistence for Dulaglutide (DU) vs. Basal Insulin (BI) in Injection-Naïve Patients with Type 2 Diabetes (T2D): The DISPELTM Study. Diabetes. 68(Supplement_1). 3 indexed citations

10.

Mody, Reema, Qing Huang, Maria Yu, et al.. (2018). Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States. Diabetes Obesity and Metabolism. 21(4). 920–929. 72 indexed citations

11.

Gallwitz, Baptist, Samuel Dagogo‐Jack, Vivian T. Thieu, et al.. (2017). Effect of once‐weekly dulaglutide on glycated haemoglobin ( HbA1c ) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c. Diabetes Obesity and Metabolism. 20(2). 409–418. 72 indexed citations

12.

Yu, Maria, et al.. (2017). Characteristics Associated with the Choice of First Injectable Therapy Among US Patients With Type 2 Diabetes. Clinical Therapeutics. 39(12). 2399–2408. 15 indexed citations

13.

Yu, Maria, et al.. (2017). Patient-reported Outcomes in Patients with Type 2 Diabetes Treated with Dulaglutide Added to Titrated Insulin Glargine (AWARD-9). Clinical Therapeutics. 39(11). 2284–2295. 17 indexed citations

14.

Jabbar, Abdul, et al.. (2017). CREED study: Hypoglycaemia during Ramadan in individuals with Type 2 diabetes mellitus from three continents. Diabetes Research and Clinical Practice. 132. 19–26. 84 indexed citations

15.

Singh, Sonal, Eugene E. Wright, Anita Y. M. Kwan, et al.. (2016). Glucagon‐like peptide‐1 receptor agonists compared with basal insulins for the treatment of type 2 diabetes mellitus: a systematic review and meta‐analysis. Diabetes Obesity and Metabolism. 19(2). 228–238. 67 indexed citations

16.

Yu, Maria, et al.. (2015). Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation. Clinical Therapeutics. 38(1). 149–160. 25 indexed citations

17.

Eby, Elizabeth L., et al.. (2014). Predictors of 30 day hospital readmission in patients with type 2 diabetes: a retrospective, case–control, database study. Current Medical Research and Opinion. 31(1). 107–114. 43 indexed citations

18.

Lu, Chieh‐Hsiang, Ta-Jen Wu, Kuang‐Chung Shih, et al.. (2012). Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus. Journal of the Formosan Medical Association. 112(3). 144–150. 12 indexed citations

19.

Grossman, Loren D., et al.. (2009). Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. Clinical Therapeutics. 31(1). 74–88. 6 indexed citations

20.

Yu, Maria, et al.. (2003). Multi-Disciplinary Design Optimization of a LH2 Turbopump Design. 39th AIAA/ASME/SAE/ASEE Joint Propulsion Conference and Exhibit.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact